Studies how PSMA PET scans may predict outcomes in prostate cancer
Observes prostate cancer patients who had PSMA PET scans, comparing scan results with clinical scores.
Plain-language title generated from the registry record
Registry title: PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer
Key facts
- Where
- Essen, GermanySee the site
Where in Germany
- University Hospital EssenEssen, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Essen
- Trial code
- NCT06320223
- Record updated
- 20 March 2024
- Original description
Background:Read full original descriptionShow less
PROMISE Registry on Standardized Evaluation of PSMA-PET and Outcome in Prostate Cancer
Background:
PROMISE criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) PET whole-body stage of prostate cancer. PSMA PET disease extent by PROMISE has been associated with oncologic outcome.
Need:
Improved prognostication across various stages of prostate cancer is needed for management guidance and study design.
Aim:
1. To assess the prognostic value of PSMA PET 2. To compare the prognostic value of PSMA PET with clinical prognostic scores in patients with prostate cancer at various disease stages
Inclusion:
* Adult patients with * biopsy/histo proven prostate cancer who * underwent PSMA PET (any type) * for staging or re-staging at any stage and who * have at least 3-year overall survival follow-up data available will be included consecutively.
Exclusion:
* Patients with neuroendocrine prostate cancer * Patients with metastasized or disseminated malignancy other than prostate cancer
Inclusion:; Adult patients with; biopsy/histo proven prostate cancer who; underwent PSMA PET (any type); for staging or re-staging at any stage and who; have at least 3-year overall survival follow-up data available will be included consecutively; Exclusion:; Patients with neuroendocrine prostate cancer; Patients with metastasized or disseminated malignancy other than prostate cancer.